RLX Technology Reports 2022 Fiscal Year Financial Performance

Mar.10.2023
RLX Technology Reports 2022 Fiscal Year Financial Performance
RLX Technology released unaudited financial results showing a year-on-year decline in revenue and profit for 2022.

On March 10th, RLX Technology, also known as Yuè Kè, announced its unaudited financial results for the year ended December 31st, 2022, and its Q4 financial results on the NASDAQ website. The company's consolidated financial report showed that its net revenue for the full year of 2022 was RMB 5.33 billion, a 37.41% decrease compared to RMB 8.52 billion in 2021. Its net profit for 2022 was RMB 1.409 billion, compared to RMB 2.028 billion in 2021.


Financial summary for the fourth quarter of 2022.


The net revenue for the fiscal year 2022 was 340 million yuan (49.3 million USD), which is a decrease of 82.14% compared to the same period in 2021, where it was 1.9044 billion yuan. The gross profit margin for the year was 43.6%, compared to last year's 40.2%. The net loss under US GAAP was 225.1 million yuan (32.6 million USD), while last year's net profit under US GAAP was 494.4 million yuan. The non-US GAAP net income for the year was 249.7 million yuan (36.2 million USD), compared to last year's 536.5 million yuan. This is a summary of the financial results for the fiscal year 2022.


In the fiscal year of 2022, the net revenue for the company was 53.328 billion Yuan (7.732 billion USD), a decrease from the previous year's revenue of 85.210 billion Yuan. The gross profit margin for 2022 was 43.2%, slightly higher than the previous year's margin of 43.1%. Under the Generally Accepted Accounting Principles in the United States, the net revenue for 2022 was 14.087 billion Yuan (2.042 billion USD), down from the previous year's revenue of 20.281 billion Yuan. The non-US GAAP net revenue for 2022 was 15.749 billion Yuan (2.283 billion USD), a decrease from the previous year's revenue of 22.515 billion Yuan.


References:


RLX Technology has released its financial results for the fourth quarter and fiscal year 2022, which have not been audited.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
China has for the first time issued clear regulatory rules for nicotine pouches and other oral nicotine products, formally classifying them under the tobacco monopoly alongside cigarettes and tobacco, ending a long-standing legal grey zone and laying the regulatory groundwork for their potential domestic launch.
Jan.09 by Alan Zhao | 2Firsts Perspectives
SICPA Secures Five-Year UK Vape Tax Stamp Contract
SICPA Secures Five-Year UK Vape Tax Stamp Contract
HM Revenue and Customs (HMRC) has awarded a five-year contract to Swiss technology company SICPA and Cartor Security Printers to implement the United Kingdom’s new vaping duty stamp and track-and-trace system, beginning in April 2026.
Market
Feb.24
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
A Louisiana lawmaker has introduced HB 302, which would prohibit businesses from selling vapor products within 300 feet of schools. The bill would measure the distance by a person walking on the sidewalk from the nearest point on school property to the nearest point of the business. It would also give the commissioner authority to modify how the distance is calculated, while maintaining the 300-foot limit.
Feb.26 by 2FIRSTS.ai
Cambodia: Phnom Penh authorities seize 2,000+ vape devices and arrest two alleged distributors
Cambodia: Phnom Penh authorities seize 2,000+ vape devices and arrest two alleged distributors
Kiripost reports that authorities seized more than 2,000 electronic smoking devices and arrested two alleged distributors in Phnom Penh’s Toul Kork district, prompting health advocates to warn that inconsistent enforcement is undermining Cambodia’s crackdown on illegal e-cigarettes and shisha.
Jan.13 by 2FIRSTS.ai
Product | Pixx Nicotine Toothpicks Listed on UK Retail Website, Said to Be Unaffected by Upcoming Vape Tax
Product | Pixx Nicotine Toothpicks Listed on UK Retail Website, Said to Be Unaffected by Upcoming Vape Tax
2Firsts has noted that a nicotine toothpick product named Pixx has appeared on a UK retailer website. The product page describes it as a smoke-free nicotine product, and the packaging image shows “UK MADE.” A nicotine-industry professional wrote on LinkedIn that the UK is set to introduce vape tax changes that may increase pressure on the retail side, and said Pixx is expected not to be included in the upcoming vape tax.
Mar.05 by 2FIRSTS.ai